©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jun 27, 2023; 15(6): 1149-1158
Published online Jun 27, 2023. doi: 10.4240/wjgs.v15.i6.1149
Published online Jun 27, 2023. doi: 10.4240/wjgs.v15.i6.1149
Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei
Ying Zhang, Xin Zhao, Chao Gao, Lin-Yu Lin, Yan Li, Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Author contributions: Zhao X and Gao C collected the data; Zhang Y and Lin LY performed the data analysis; Zhang Y wrote the original draft preparation; Zhang Y and Li Y wrote the review and editing; Li Y contributed to the supervision.
Supported by Beijing Municipal Administration of Hospitals’ Ascent Plan , No. DFL20180701 ; and Beijing Municipal Grant for Medical Talents Group on Peritoneal Surface Oncology , No. 2017400003235J007 .
Institutional review board statement: This study was reviewed and approved by the ethics committee of Beijing Shijitan Hospital, Capital Medical University, No. sjtkyll-lx-2022(066).
Informed consent statement: All study participants or their legal guardian provided written informed consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: We have no data to share.
Corresponding author: Yan Li, MD, PhD, Doctor, Surgical Oncologist, Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian Street, Haidian District, Beijing 100038, China.
Received: March 8, 2023
Peer-review started: March 8, 2023
First decision: March 15, 2023
Revised: March 18, 2023
Accepted: April 14, 2023
Article in press: April 14, 2023
Published online: June 27, 2023
Processing time: 99 Days and 8.4 Hours
Peer-review started: March 8, 2023
First decision: March 15, 2023
Revised: March 18, 2023
Accepted: April 14, 2023
Article in press: April 14, 2023
Published online: June 27, 2023
Processing time: 99 Days and 8.4 Hours
Core Tip
Core Tip: For systemic chemotherapy of advanced pseudomyxoma peritonei (PMP), there are currently few studies and insufficient evidence. In this study, the bevacizumab combined with cyclophosphamide and oxaliplatin regimen was used for advanced PMP for the first time. The scheme used in this study was based on clinical experience and had achieved good results.